Roivant Sciences opened lower at $37.11, compared with its previous close of $37.52. In the last trading session, the stock traded between $37.00 and $37.94. It showed a downward intraday trend.
return calculator
Time Period
An investment of $100 made 5 years ago in Roivant Sciences is now worth
$ 468.82
giving a profit of
$ 368.82 (368.82%)
invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 11 Analysts
Buy
81.82%
Hold
18.18%
Sell
0%
Markets Today
Today's Change
$-0.30 (-0.79%)
Day High
$37.94
Day Low
$37.00
Day Open
$37.11
Prev Close
$37.52
Volume
10,72,111
1W Return
-0.60%
1M Return
1.95%
3M Return
13.29%
6M Return
35.26%
1Y Return
98.42%
Fundamentals
Market Cap ($ Mn)
26,888
PE Ratio
-
PB Ratio
5.93
PEG Ratio
-
ROE
-13.80%
ROCE
-15.76%
EPS (TTM)
$-0.26
Investment Returns
1 Week
-0.60%
1 Month
1.95%
3 Months
13.29%
6 Months
35.26%
9 Months
69.05%
Financials
Quarterly
All values in $ Mn
7.6
Mar 25
2.2
Jun 25
1.6
Sep 25
2.0
Dec 25
2.5
Mar 26
1.4
Jun 26
Updates
29Oct
Citigroup raises Roivant Sciences price target to $56, maintains Buy
Citigroup raises Roivant Sciences price target from $46 to $56. Analyst Samantha Semenkow maintains a Buy rating on the stock. The price target increase reflects a $10 upside revision.
Yesterday
5Oct
Roivant Sciences holds $4B cash, receives $950M Moderna settlement
Roivant Sciences holds cash of just under $4 billion as of Q1 FY26. Received $950 million upfront settlement from Moderna, boosting liquidity. R&D expenses stood at ~$200 million, with non-GAAP G&A at ~$100 million. Brepocitinib launch for dermatomyositis expected by end of September. Accelerated share repurchases totaling ~$200 million executed in the quarter.
25 days ago
8Sep
Roivant's mosliciguat cuts vascular resistance 56% in Phase 2 trial
PHocus Phase 2 trial met primary endpoint with -56.3% placebo-adjusted PVR reduction at Week 16. Secondary endpoints showed +35.2m improvement in six-minute walk distance and -53.2% drop in NT-proBNP. Mosliciguat demonstrated lower cough incidence (12.1%) compared to placebo (18.2%) in PH-ILD patients. Roivant initiated Phase 3 PHrontier trial to advance potential first-in-class inhaled sGC activator.
1mo ago
1Sep
FDA approves Roivant's LISRAYA as first targeted dermatomyositis treatment
FDA approves LISRAYA as first targeted treatment for adult dermatomyositis. 55% of LISRAYA patients achieved moderate disease improvement vs 30% on placebo. 45% of treated patients eliminated steroid usage compared to 29% on placebo. Patients reported over fourfold greater improvement in overall disease activity.
1mo ago
6Aug
Roivant Sciences Q1 Results: Adj. EPS Misses, Sales Fall 34%
Roivant Sciences missed Q1 estimates with adjusted EPS of $(0.34) vs $(0.32) expected. Sales fell 33.55% YoY to $1.442 million, missing the $2.057 million forecast. Losses widened 36% compared to the prior year quarter.
